Kiora Pharmaceuticals (KPRX)

• Market cap: $8.96M
• 1 day: -1.14%
• 5 days: -3.33%
• 1 month: -10.92%
• 3 months: -13.29%
• 6 months: -20.67%
• Year to date: -27.09%
• 1 year: -23.46%
• 5 years: -99.81%
• 10 years: -99.99%
• Sector: Healthcare
• Industry: Biotechnology

About: Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.

Employees: 12

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

11% less funds holding

Funds holding: 18 [Q1] → 16 (-2) [Q2]

12.23% less ownership

Funds ownership: 42.85% [Q1] → 30.61% (-12.23%) [Q2]

25% less repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 4

31% less capital invested

Capital invested by funds: $3.87M [Q1] → $2.68M (-$1.19M) [Q2]

50% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 4

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

• Low target: $10
• Avg. target: $10
• High target: $10

1 analyst rating

• positive: 1 100%
• neutral: 0 0%
• negative: 0 0%

HC Wainwright & Co. Yi Chen

$10

Buy Reiterated

2 Sep 2025